Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients
OwnerTibor BAKÁCSinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to the combination of attenuated non-pathogenic avian double-stranded (ds) RNA viral vector (IBDV) with an anti-PD-1 antibody and/or an anti-CTLA-4 antibody for treating Hepatitis B virus (HBV) infection.
Claims12
A combination of attenuated non-pathogenic avian double-stranded (ds) RNA viral vector (IBDV) with an anti-PD-1 antibody and/or an anti-CTLA-4 antibody for use in the treatment of Hepatitis B virus (HBV) infection.
A method for the treatment of Hepatitis B virus (HBV) infection, said method comprising administering to a subject in need thereof a combination attenuated non-pathogenic avian double-stranded (ds) RNA viral vector (IBDV) with an anti-PD-1 antibody and/or an anti-CTLA-4 antibody.
Dependencies are inferred from the claim text.